LGND Earnings & Financial Statements
Ligand Pharmaceuticals Incorporated
$294.99
-$8.54(-2.81%)
69
Overall
75
Value
63
Tech
71
Quality
Market Cap
$5.88B
Volume
245.28K
52W Range
$175.89 - $326.63
Target Price
$344.25
LGND earnings and financial statements: Ligand Pharmaceuticals Incorporated's income statement, balance sheet and cash flow statement, annual and quarterly.
LGND Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $268.09M | $167.13M | $131.31M | $196.25M | $241.54M |
| Cost of revenue | $14.55M | $11.07M | $10.51M | $52.83M | $62.18M |
| Operating income | $41.00M | -$22.61M | $11.94M | $3.04M | $103.85M |
| EBITDA | $198.72M | $41.28M | $101.08M | $89.91M | $159.46M |
| Net income | $124.45M | -$4.03M | $52.15M | -$33.36M | $57.14M |
| EPS (diluted) | $6.13 | $-1.64 | $2.94 | $-1.98 | $2.06 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.56B | $941.77M | $787.22M | $762.67M | $1.30B |
| Total liabilities | $543.42M | $111.33M | $86.30M | $165.18M | $476.43M |
| Shareholders’ equity | $1.02B | $830.44M | $700.91M | $597.49M | $821.16M |
| Cash and equivalents | $174.93M | $72.31M | $22.95M | $45.01M | $19.52M |
| Long-term debt | $450.40M | $5.82M | $5.75M | $10.34M | $322.97M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $49.36M | $97.05M | $49.58M | $137.85M | $78.80M |
| Capital expenditure | -$452.0K | -$1.82M | -$53.85M | -$17.92M | -$8.76M |
| Free cash flow | $48.91M | $95.23M | $46.06M | $119.93M | $70.04M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LGND | $294.99 | -2.8% | 245.28K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ligand Pharmaceuticals Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW